1
|
Shapkina MY, Mazdorova EV, Avdeeva EM, Shcherbakova LV, Ryabikov AN, Hubachek JA, Bobak M, Malyutina SK. Changes in the prevalence of atrial fibrillation in the Russian population over a 13-year follow-up. Cardiovasc Ther Prev 2022. [DOI: 10.15829/1728-8800-2022-3108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Aim. To study the prevalence of atrial fibrillation (AF) in the Russian urban population cohort aged 45-69 years and its changes over 13-year follow-up during aging.Material and methods. This cross-sectional long-term prospective study included random population sample of men and women 45-69 years (n=9360, HAPIEE project, Novosibirsk), which was examined in 2003-2005 and was re-examined twice and followed up for about 13±1,00 years in men and 13,1±2,17 years in women. The incidence of AF was assessed for individuals without AF or cardiovascular disease (CVD) at the baseline examination. Statistical analysis was performed using the SPSS software package (v.13.0).Results. In a population sample over a 13-year follow-up, AF prevalence increased from 1,6% (1,1% among women and 2,1% among men) at the age of 45-69 years to 4,2% (3,0% among women and 6,1% among men) aged 55-84 years according to screening rest ECG examinations. The prevalence of new AF cases over a 13-year followup in the cohort of 45-69 years old without previous CVD and AF was 5,6%, of which 40% were paroxysmal. The mean age at the time of first registered AF was 69±6,93 years, and was 2 years higher in women (70,0±6,83) than in men (68±6,93). The average period before the AF onset among people aged 45-69 years without baseline CVD and AF was 7,5±3,83 years for men and 8,1±4,02 years for women. The total prevalence of AF in the population sample was 8,3%. The highest AF prevalence was registered at the age of 65-69 years (11,4%) for men and 5 years later for women (12,0%) (p80 years decreased and amounted to 4,1% among men and 5,7% among women.Conclusion. In the Russian population sample (Novosibirsk) aged 45-69, the AF prevalence increased from 1,6 to 8,3% over 13 years of follow-up. In addition, 473 new AF cases were identified, ~40% of which were paroxysmal AF. The prevalence of AF in the Siberian population sample for the 45-60 years age group is comparable with the large Russian and North American studies, but higher for persons aged 60-74 years and lower for older age group, for both men and women.
Collapse
Affiliation(s)
- M. Yu. Shapkina
- Research Institute of Internal and Preventive Medicine — branch of the Federal Research Center Institute of Cytology and Genetics
| | - E. V. Mazdorova
- Research Institute of Internal and Preventive Medicine — branch of the Federal Research Center Institute of Cytology and Genetics
| | - E. M. Avdeeva
- Research Institute of Internal and Preventive Medicine — branch of the Federal Research Center Institute of Cytology and Genetics
| | - L. V. Shcherbakova
- Research Institute of Internal and Preventive Medicine — branch of the Federal Research Center Institute of Cytology and Genetics
| | - A. N. Ryabikov
- Research Institute of Internal and Preventive Medicine — branch of the Federal Research Center Institute of Cytology and Genetics
| | | | | | - S. K. Malyutina
- Research Institute of Internal and Preventive Medicine — branch of the Federal Research Center Institute of Cytology and Genetics
| |
Collapse
|
2
|
Malyutina SK, Mazdorova EV, Shapkina MY, Avdeeva EM, Simonova GI, Hubacek JA, Bobak M, Nikitin YP, Ryabikov AN. [The frequency and profile of drug treatment in subjects with dyslipidemias and cardimetabolic diseases in an urban russian population older then 55 years]. Kardiologiia 2021; 61:49-58. [PMID: 35057721 DOI: 10.18087/cardio.2021.12.n1558] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 04/23/2021] [Accepted: 05/28/2021] [Indexed: 06/14/2023]
Abstract
Aim To analyze frequency and profile of the lipid-lowering therapy (LLT) in patients with dyslipidemia (DLP) and cardiometabolic diseases (CMD) in a population sample aged 55-84 years at the current time (2015-2017).Material and methods Despite guidelines on DLP treatment and the availability of effective and safe lipid-lowering drugs, control of DPL in primary and secondary prevention of cardiovascular diseases (CVD) is insufficient. Knowledge of the level of pharmaceutical correction of DLP in the Russian population is limited; it requires an LLT assessment in various regions and in a wide age range, and a regular monitoring taking into account changing approaches to the correction of DLP. A random population of men and women aged 55-84 years (n=3 896) was evaluated in Novosibirsk in 2015-2017 (project HAPIEE). A joint DLP category was established as low-density lipoprotein cholesterol (LDL-C) ≥3.0 mmol/l, or total cholesterol (TC) ≥5.0 mmol/l, or triglycerides (TG) ≥1.7 mmol/l, or LLT. The combined group of DLP and CMD included ischemic heart disease (IHD), type 2 diabetes mellitus (DM2), and DLP. Regular LLD treatment for the recent 12 months, excluding the dosage of medicines, was assessed using the Anatomic Therapeutic Chemical (ATC) classification. The conditional control of serum lipids was taken as the achievement of LDL-C <3.0 mmol/l, TC <5.0 mmol/l, and TG <1.7 mmol/l.Results In the study sample, the total prevalence of DLP and CMD was 88 % (82.8 % for men and 91.3 % for women, p<0.001). 48.3% of patients in the IHD group, 35.0% in the DM2 group, 29.4% in the DLP group, and 32.8% in the CMD group took LLT. Control of serum lipids was achieved in 18.3% (37.9 % of patients on LLT) of patients with IHD; 9 % (25.6 % of patients on LLT) of patients with DM2; 7.3 % (24.8 % of patients on LLT) of patients with DLP; and 9.0 % (27.6 % of patients on LLTсреди) in the DLP and CMD group. Women with DM2 and DLP more frequently achieved lipid control than men (p<0.001). 98.7 % of study participants took statins as LLT.Conclusion In the sample of urban population aged 55-84 years in 2015-2017, 90 % of patients had DLP or CMD, and at least ¾ of them required blood lipid control. The lipid control was achieved in every fifth IHD patient and in approximately 40% of those who took LLT. For DM2 or DLP patients, the lipid control was achieved in every tenth patient and in approximately 25% of those receiving LLT. Frequency of lipid control in IHD patients was comparable for men and women; in DM2 and DLP, men less frequently achieved the lipid control than women. About 70% of patients in the combined DLP and CMD group and more than 50% of IHD patients did not take LLT, which considerably contributed to the insufficient lipid control in primary and secondary prevention of atherosclerotic CVDs in this population.
Collapse
Affiliation(s)
- S K Malyutina
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk
| | - E V Mazdorova
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk
| | - M Yu Shapkina
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk
| | - E M Avdeeva
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk
| | - G I Simonova
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk
| | - J A Hubacek
- Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague
| | - M Bobak
- University College London, London
| | - Yu P Nikitin
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk
| | - A N Ryabikov
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk
| |
Collapse
|
3
|
Malyutina SK, Mazdorova EV, Shapkina MY, Avdeeva EM, Maslacov NA, Simonova GI, Bobak M, Nikitin YP, Ryabikov AN. [The profile of drug treatment in subjects aged over 50 years with hypertension in an urban russian population]. ACTA ACUST UNITED AC 2020; 60:21-29. [PMID: 32375612 DOI: 10.18087/cardio.2020.3.n948] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2019] [Accepted: 02/17/2020] [Indexed: 11/18/2022]
Abstract
Objective To analyze a profile of hypotensive drug therapy in patients with arterial hypertension (АH) aged 55-84 in a sample of urban population at a current period of time (2015-2017).Materials and Methods AH is a leader among risk factors of cardiovascular diseases (CVD) due to its high prevalence and serious prognosis. Despite the availability of effective hypotensive drugs and guidelines on AH treatment, 50% of patients do not achieve blood pressure (BP) goals. Knowledge about drug correction of AH in the Russian population is limited to clinical studies. Taking into account changing approaches in management of patients with AH, the population-based evaluation of hypotensive treatment if relevant. A random population sample of males and females aged 55-84 (n=3.898) was evaluated in Novosibirsk in 2015-2017 (international project, Health, Alcohol and Psychosocial Factors in Eastern Europe (HAPIEE)). AH was diagnosed in presence of systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg and/or treatment with hypotensive drugs within the recent two weeks. Regular intake of medication for 12 months was evaluated with coding according to the Anatomic Therapeutic Chemical Classification System (АТХ / АТС).Results In the population sample aged 55-84, AH prevalence was 80.9 %, and 21.1 % of persons with AH did not receive drug therapy. Hypotensive medicines included (total/as a part of combination therapy) angiotensin-converting enzyme (ACE) inhibitors (42.3 % / 25.3 %), angiotensin II receptor blockers (ARBs) (30.3 % / 18.9 %), diuretics (22.6 % / 20.4 %), calcium channel blockers (20.2 % / 16.1 %), and beta-blockers (34.7 % / 27.6 %). 45.7 % of people with AH received a combination therapy. Effective BP control was achieved in 23.4 % of AH patients and in 29.6 % of patients receiving a hypotensive therapy. In the group of ineffective BP control, the proportion of females was lower, AH duration was longer, and blood glucose was higher than in the group of effective control.Conclusion In the sample of urban population aged 55-84 in 2015-2017, each fourth participant with AH and each third participant using hypotensive drugs achieved effective BP control. The therapy profile in AH patients included recommended drug classes. However, combination therapy was used insufficiently (50% of AH patients). By frequency of use, ACE inhibitors were on the first place, beta-blockers were on the second place, ARBs were on the third place, diuretics were on the fourth place, and calcium channel blockers were on the fifth place, which differed from the guidelines (the difference from the recommended priority ranking is that the drugs taking the first places in the guidelines were in fact on the 3rd and 4th places in their actual frequency of use). 20% of persons with AH did not receive hypotensive therapy, which significantly contributed to the insufficient BP control in the population.
Collapse
Affiliation(s)
- S K Malyutina
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
| | - E V Mazdorova
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
| | - M Y Shapkina
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
| | - E M Avdeeva
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
| | - N A Maslacov
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
| | - G I Simonova
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
| | - M Bobak
- University College London, Department of Epidemiology & Public Health
| | - Yu P Nikitin
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
| | - A N Ryabikov
- Research Institute of Internal and Preventive Medicine, Branch, Federal Research Center, Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences
| |
Collapse
|